T cell activation regulates CD6 alternative splicing by transcription dynamics and SRSF1 by Araújo, Mafalda Martins de et al.
of June 23, 2014.
This information is current as
SRSF1
Splicing by Transcription Dynamics and 
T Cell Activation Regulates CD6 Alternative
Alexandre M. Carmo and Alexandra Moreira
Mafalda Santos, Rafaela Leal, Sérgio F. de Almeida, 











, 30 of which you can access for free at: cites 67 articlesThis article 
Subscriptions
http://jimmunol.org/subscriptions
 is online at: The Journal of ImmunologyInformation about subscribing to 
Permissions
http://www.aai.org/ji/copyright.html
Submit copyright permission requests at: 
Email Alerts
http://jimmunol.org/cgi/alerts/etoc
Receive free email-alerts when new articles cite this article. Sign up at: 
Print ISSN: 0022-1767 Online ISSN: 1550-6606. 
Immunologists, Inc. All rights reserved.
Copyright © 2014 by The American Association of
9650 Rockville Pike, Bethesda, MD 20814-3994.
The American Association of Immunologists, Inc.,
 is published twice each month byThe Journal of Immunology
 by A
lexandre Carm




















The Journal of Immunology
T Cell Activation Regulates CD6 Alternative Splicing by
Transcription Dynamics and SRSF1
Vaˆnia G. da Glo´ria,* Mafalda Martins de Arau´jo,†,‡,x Ana Mafalda Santos,†
Rafaela Leal,* Se´rgio F. de Almeida,{ Alexandre M. Carmo,†,‖ and Alexandra Moreira*
The T cell-surface glycoprotein CD6 is a modulator of cellular responses and has been implicated in several autoimmune diseases
such as multiple sclerosis, rheumatoid arthritis, and psoriasis. During Ag presentation, CD6 is targeted to the immunological syn-
apse in a ligand binding-dependentmanner, in which CD6 domain 3 directly contacts CD166, expressed on the APC. T cell activation
results in the induction of CD6Dd3, an alternatively spliced isoform that lacks the ligand-binding domain and thus no longer
localizes at the immunological synapse. In this study, we investigated the molecular mechanisms regulating the expression of
CD6Dd3 upon human primary T cell activation. Using chromatin immunoprecipitation, we observed an increase in RNA poly-
merase II occupancy along the CD6 gene and augmented CD6 transcription. We showed that activation leads to transcription-
related chromatin modifications, revealed by higher CD6 acetylation levels. Modulation of chromatin conformation using a his-
tone deacetylase inhibitor that increases transcription rate causes an increase of exon 5 skipping. We further showed that the
splicing factor SRSF1 binds to a regulatory element in CD6 intron 4, activating exon 5 splicing and promoting exon 5 inclusion.
Concomitant with T cell activation-induced exon 5 skipping, we observed a downregulation of SRSF1. Using RNA immunopre-
cipitation, we showed that in activated T cells, SRSF1 recruitment to the CD6 transcript is impaired by increased chromatin
acetylation levels. We propose that upon T cell activation, SRSF1 becomes limiting, and its function in CD6 exon 5 splicing
is countered by an increase in CD6 transcription, dependent on chromatin acetylation. The Journal of Immunology, 2014, 193:
391–399.
T
he CD6 cell-surface Ag is a type I transmembrane gly-
coprotein mostly expressed on thymocytes and mature T
and B1a lymphocytes (Tand B1 cells) (1). CD6 belongs to
the scavenger receptor cysteine–rich (SRCR) superfamily of
protein receptors, containing three cysteine-rich domains in its
extracellular region (2). Human CD6 is encoded by 13 exons, of
which the first 7 encode the amino terminal sequence and the
extracellular and transmembrane regions, whereas the remaining 6
exons code for the cytoplasmic tail. Each of the three extracellular
SRCR domains (d1–d3) is coded by a separate exon (e3–e5).
The functional role of CD6 has not been definitively established.
Whereas it is undeniable that increased expression of CD6 results in
repression of TCR-mediated signaling (3, 4), the direct binding of
CD6 with specific Abs or recombinant ligand may enhance cel-
lular responses, presumably through the induced aggregation of
protein kinases associated with the cytoplasmic tail of CD6 (3, 5,
6). Notwithstanding the uncertain nature of CD6, possibly even
having a dual role, the fact is that CD6 impacts on cell growth and
differentiation, and misregulation of the function of CD6 may
result in physiological imbalances and autoimmunity. CD6 has
been associated with several autoimmune diseases such as mul-
tiple sclerosis (7, 8), rheumatoid arthritis (9), psoriasis (10), and
Sjo¨gren’s syndrome (11) and has been considered as a possible
therapeutic target for some of these pathologies (12).
The known ligand for CD6 is the Ig super family receptor CD166,
expressed on conventional APC and also in thymic epithelia, with
the CD6–CD166 interaction being determinant on thymocyte se-
lection (13). CD166 is additionally expressed in the epithelial layer
of the blood–brain barrier and enables the transmigration of CD4+
T cells into the brain (14). The interaction between CD6 and CD166
involves the binding of the membrane distal Ig super family domain
of APC surface-expressed CD166 to the membrane-proximal SRCR
domain 3 of CD6 (15). Importantly, this interaction is fairly strong
and can help with strengthening and stabilizing T cell–APC con-
tacts (16). Localization and function of both CD6 and CD166 at the
immunological synapse (IS) are determined by and reliant on this
binding, and conversely, a naturally occurring alternative splicing–
dependent CD6 isoform that lacks domain 3, CD6Δd3, fails to
target and recruit CD166 to the IS (17).
CD6Δd3 mRNA is expressed in 40% of T lymphocytes, being
the dominant isoform in one-quarter of this subpopulation in rats
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(17). However, upon CD3 plus CD28 stimulation, ∼90% of T cells
coexpress CD6Δd3 together with full-length CD6, implying that
a large proportion of CD6 molecules is not capable of remaining
positioned at the interface with the APC during physiological
T cell activation. Double-positive thymocytes show a decrease
in the proportion of CD6Δd3, whereas in single-positive CD4 or
CD8 thymocytes, CD6Δd3 is expressed in 50% of the cells.
Analysis of CD6 isoforms at the protein level is made possible in
human T cells due to the availability of mAbs against the different
SRCR domains. Concordant with the analysis in the rat system,
activation of human T cells induces a large proportion of full-
length CD6 protein to be replaced by the CD6Δd3 isoform. As
the total amount of CD6 remains roughly constant, this suggests
that a significant displacement of CD6 away from the IS occurs
during the course of activation. The downmodulation of domain 3
of CD6 thus reveals not only a very interesting mode of positional
control of cell surface receptors in physiological processes such as
cell activation and thymocyte selection, but also can have an
impact on the development of pathology. A recent study showed
that the multiple sclerosis–associated SNP rs17824933GG in intron
1 of CD6 was associated with an increase of CD6Δd3 and de-
crease of full-length CD6 expression in T cells, which resulted in
a diminished long-term proliferation of CD4+ T cells, suggesting
the involvement of CD6Δd3 in the disease (18).
Alternative splicing in cells of the immune system is physio-
logically relevant, as it allows a diversified number of cellular
responses and results in a rapid adaptation to the challenging
environment (19). However, the molecular mechanisms involved
in some of these alternative splicing events, in particular those
occurring during T cell activation, are mostly uncharacterized. A
few examples of alternative spliced transcripts in the immune
system context have been described. One of the first examples was
the IgH, which encodes both membrane-associated and secreted
proteins through alternative RNA processing reactions (20). An-
other example is the alternative splicing of exon v5 of CD44, which
is regulated by phosphorylated SAM68, an Erk target (21). The
Ras–MAPK pathway has also been implicated in regulating exon 4
alternative splicing of CD45 during T cell development, via gly-
cogen synthase kinase 3 (22). The IL-7Ra alternative splicing is
another example: when exon 6 is skipped, the receptor loses the
transmembrane domain and is secreted (23). Fas is also regulated by
alternative splicing of the exon 6 by FASTK-associated with TIA1/
TIAR and other splicing factors: a receptor with a proapoptotic
function is produced when exon 6 is included and with an anti-
apoptotic function when exon 6 is excluded (24).
The regulation of alternative splicing is dictated by RNA cis-
elements that are frequently located in the alternative exon and
in the flanking introns. These elements can be exonic or intronic
splicing enhancers (ISE), stimulating the recognition of the
splicing sites that are flanking the exon or exonic or intronic
silencers inhibiting this recognition by the spliceosome machinery
(25). These elements are binding sites for silencing factors,
heterogeneous nuclear ribonucleoproteins (hnRNPs), enhancer
factors, or serine/arginine-rich proteins (26–30). Additionally,
chromatin structure and histone modifications such as methyl-
ations and acetylations affect RNA polymerase II (RNA pol II)
elongation rate and recruit splicing factors through adaptor pro-
teins, acting as a bridge between the processes of transcription and
splicing (31–37). Transcription elongation factors or drugs that
promote an open chromatin state, such as trichostatin A (TSA),
favor an increase of RNA pol II elongation rate, increasing exon
skipping (35, 38, 39). In contrast, inhibition of RNA pol II elon-
gation rate usually results in the augmented inclusion of an al-
ternative exon (40–42).
Alternative splicing of exon 5 in the CD6 gene is physiologically
and functionally relevant, as the differential expression of the
membrane-proximal SRCR domain coded by that exon determines
CD6 and CD166 localization or exclusion from the IS. In this study,
we show that activation-induced CD6 exon 5 skipping in T cells
involves the downmodulation and recruitment of the SRSF1 splicing
factor to an ISE in CD6 intron 4 that together with an increase in the
RNA pol II transcription rate of the CD6 gene contribute to the
production of a CD6 isoform devoid of the ligand-binding domain.
Materials and Methods
Cell isolation and drugs treatment
Buffy coats from healthy donors were provided by Hospital Sa˜o Joa˜o,
Servic¸o de Imunohemoterapia (Porto, Portugal), and PBMCs were isolated
by density-gradient separation using Lympholyte-H (Cedarlane Labora-
tories). T cells were isolated from PBMCs using the Easysep Human T Cell
Enrichment Kit (StemCell Technologies). Cells were maintained in RPMI
1640 Glutamax with 10% FBS, 1% sodium pyruvate, and 1% penicillin-
streptomycin (Life Technologies). T cells were stimulated overnight with
PHA-P at 10 mg/ml or with a combination of anti-CD3 (OKT3) at 2 mg/ml
and anti-CD6 (MEM-98) at 10 mg/ml. In chromatin-modulation experiments,
63 106 cells were treated with 0.5 mMTSA or with 10 mM camptothecin for
1 h at 37˚C.
Plasmids
To construct the CD6 minigene, the genomic DNA region from exon 4–6
was amplified by PCR and cloned into the pCMVdi vector (kindly given by
Juan Valca´rcel, Centre de Regulacio´n Geno´mica, Barcelona, Spain). Intron
4 mutants were made by PCR site-directed mutagenesis using Phusion
DNA polymerase (Fynnzymes). T7 epitope–tagged vectors pCGT7SF2,
pCGT7SRp20, and pCGT7A1 used for overexpression of the splicing
factors SRSF1, SRSF3, and hnRNPA1, respectively, were a kind gift from
Javier Ca´ceres (Medical Research Council, Edinburgh, U.K.).
Transfections
Cells were transfected by nucleofection using the Amaxa Human T Cell
Nucleofactor kit (Lonza). A total of 2 mg each CD6 minigene mutant or
T7-tagged expression vectors were used for cell transfections (Supplemental
Fig. 4A). For the knocking down experiments, PBMCs were transfected with
small interfering RNAs (siRNAs; Sigma-Aldrich) (SRSF1, 59-ACGAUUG-
CCGCAUCUACGU-39; SRSF3#1, 59-CGAAGUGUGUGGGUUGCUA-39;
SRSF3#2, 59-GAGAAGUGGUGUACAGGAA-39; hnRNPA1#1, 59-CCAC-
UUAACUGUGAAAAAGAUAUUU-39; and hnRNPA1#2, 59-CUUUGGU-
GGUGGUCGUGGA-39) at a final concentration of 50 nM for SRSF1 and
SRSF3 and 300 nM for hnRNPA1 (Supplemental Fig. 4B, 4C). Total RNA
and protein extracts were isolated after 48 h of incubation at 37˚C, 5% CO2.
Cell fractionation and RNA extraction
Cells were washed twice with ice-cold PBS and centrifuged for 5 min at
290 3 g at 4˚C. The cell pellet was resuspended in 1 ml RSB buffer
(10 mM Tris-Cl pH 7.4, 10 mM NaCl, and 3 mM MgCl2) and incubated 3
min on ice. Cells were pelleted at 1500 3 g for 3 min at 4˚C, the super-
natant was discarded, and the cells were lysed by gentle resuspension
in 150 ml RSBG40 buffer (10 mM Tris-Cl [pH 7.4], 10 mM NaCl, 3 mM
MgCl2, 10% glycerol, and 0.5% Nonidet P-40). Samples were centrifuged
at 4500 3 g for 3 min at 4˚C. The supernatant (cytoplasmic fraction) was
collected in a new Eppendorf tube (Eppendorf), and 1 ml TRIzol (Invi-
trogen) was added to extract cytoplasmic RNA according to the manu-
facturer’s protocol. The nuclei pellet was also resuspended in 1 ml TRIzol
(Invitrogen) to extract the nuclear RNA.
RT-PCR
Total RNA from human primary T cells was isolated using TRIzol (Invi-
trogen), and 500 ng RNA for each condition was treated with DNAse I
(Roche). cDNAwas synthetized using Superscript III reverse transcriptase
(Invitrogen) according to the manufacturer’s protocol. A total of 25% of the
RT reaction volume was used to analyze endogenous CD6 exon 5 alter-
native splicing pattern by PCR amplification with Go Taq DNA poly-
merase (Promega). In the case of CD6 minigene mutants, cDNA was
synthesized with a plasmid RT primer, and radiolabeled primers were used
in a low-cycle (20 cycles) PCR reaction. Quantitative PCR (qPCR) reac-
tions were performed with a 1:10 cDNA dilution using IQ SYBR Green
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Supermix (Bio-Rad) and following the manufacturer’s instructions. Primer
sequences are available upon request. Due to donor variability, the resting
CD6 exon 5 splicing pattern was confirmed prior to analysis.
Western blotting
Whole-cell lysates were prepared, resolved, and transferred with the iBlot
gel transfer device (Life Technologies). Incubations with primary Abs
diluted in TBST containing 3% nonfat dried milk were followed by washes
with TBST, incubation with the appropriate secondary Abs in TBST/dried
milk, and detection using enhanced chemiluminescence (ECL Prime;
Amersham/GE Healthcare). Abs used were: anti-SRSF1 (AK96, a kind gift
fromAdrianKrainer, Cold Spring Harbor Laboratory), anti-hnRNPA1 (9H10;
kind gift from Gideon Dreyfuss, Howard Hughes Medical Institute), and anti-
SRp20 (7B4-sc13510; Santa Cruz Biotechnology).
Chromatin and RNA immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed using human T cells
as previously described (37). The relative occupancy of the immunopreci-
pitated protein at each DNA site was estimated as follows: 2Ct (input)2Ct (IP),
where Ct (input) and Ct (IP) are mean threshold cycles (Ct) of quantitative
RT-PCR done in duplicate on DNA samples from input and specific
immunoprecipitations, respectively. Abs used: rabbit polyclonal anti–Pol II
(N20; Santa Cruz Biotechnology); anti–histone H3 (ab1791; Abcam); anti-
H3K36me3 (ab9050; Abcam); anti-H3K9me3 (ab8898; Abcam), and anti-
H3K9Ac (ab10812; Abcam). Primer sequences are available upon request.
RNA immunoprecipitation (RIP) was performed using the EZ-Magna
RIP RNA-Binding Protein Immunoprecipitation Kit (Merck Millipore).
A rabbit mAb anti-SRSF1 (ab133689; Abcam) was used. The relative
occupancy of the immunoprecipitated protein at each RNA site was esti-
mated as described above for the ChIP assay.
UV-crosslinking immunoprecipitation assays
A total of 5000 cpm of intron 4 premRNA probes were incubated in 50-ml
reaction mixtures containing 100 mg PBL nuclear extracts, 32 mM HEPES
(pH 7.9), 1.56 mM MgCl2, 0.5 mM ATP, 20 mM creatine phosphate, and
2.6% polyvinyl alcohol. Samples were incubated at 30˚C for 20 min, UV-
crosslinked in a Hoefer UVC 500 Ultraviolet Crosslinker (254 nm for
9 min, 4 cm from light source; Hoefer), and treated with 5 mg RNase A
(1 mg/ml) at 37˚C for 30 min. A 10% aliquot of the cross-linked samples
was loaded on a 12% SDS-PAGE. For immunoprecipitation, 100 ml tissue
culture supernatant of monoclonal anti-SRSF1 Ab (AK96) and 35 ml
Protein A Sepharose beads 50% slurry (#CL-4B-200; Sigma-Aldrich) were
added to 80% cross-linked material, and 0.1 M KCl Buffer D was added to
a final volume of 200 ml. The mixture was incubated overnight at 4˚C in
a rotative wheel. Beads were washed two times with ice-cold Binding
Buffer I (20 mM HEPES [pH 7.9], 150 mM NaCl, and 0.05% Triton X-
100) and two times with ice-cold Binding Buffer II (20 mM HEPES [pH
7.9], 150 mM NaCl, and 1% Triton X-100). After the last wash, the su-
pernatant was completely removed, and beads were resuspended in 35 ml
23 SDS-loading dye and heated for 5 min at 95˚C. After centrifugation,
the supernatant was loaded on a 12% SDS-PAGE. Gels were fixed for
35 min at room temperature in a fixing solution before drying. Gels were
exposed to a radiographic film.
Results
Modulation of chromatin structure affects CD6 exon 5 skipping
in human primary T lymphocytes
We have previously shown that skipping of exon 5 of CD6 is
induced by T cell activation, resulting in an increase of the
CD6Dd3 mRNA isoform, which is translated into a CD6 poly-
peptide that lacks the domain of interaction with its ligand, CD166
(schematically represented in Fig. 1A) (17). To investigate the
molecular mechanisms regulating T cell activation–dependent
alternative splicing of CD6, we first confirmed the pattern of exon
5 skipping in human PBMCs activated with the mitogenic lectin
PHA-P. As expected, PHA induced a switch in the exon 5 alter-
native splicing pattern, resulting in a .2-fold decrease of the ratio
between the CD6 full-length mRNA isoform (CD6FL) and the
isoform omitting exon 5 (CD6Dd3) (Fig. 1B, 1C). This switch is
also observed in purified T cells activated with anti-CD3 and anti-
CD6 mAbs (Supplemental Fig. 1).
It was also apparent that activation with PHA induced an in-
crement in the levels of the full-length mRNA isoform, suggesting
a general transcriptional induction (Fig. 1b). To understand how
transcription of CD6 was regulated upon T cell activation, we
purified T lymphocytes from blood and analyzed changes in RNA
pol II occupancy in the CD6 gene and CD6 expression levels
occurring in resting and activated T cells using ChIP (Fig. 2).
Upon T cell activation, an overall increase of RNA pol II occu-
pancy throughout the CD6 gene was observed (Fig. 2b), concur-
ring with an increase in CD6 transcription (Fig. 2c).
Accumulating evidence indicates that alternative splicing is
influenced by chromatin histone modifications (43), in particular
H3K36me3 and H3K9me3 (32, 33). To investigate whether these
regulatory mechanisms could also govern CD6 exon 5 alternative
splicing, we analyzed the pattern of H3K36me3 and H3K9me3 in
the CD6 gene, in resting and activated T cells. H3K36me3 levels
were increased in the body of the gene compared with the first
exon and the intergenic region (Supplemental Fig. 2A), as it
occurs in actively transcribed genes (44). H3K9me3 levels that
were described to be enriched in a subset of alternative exons (33)
were decreased in the body of the CD6 gene in comparison with
the intergenic region (Supplemental Fig. 2B). However, there were
no differences in H3K36me3 and H3K9me3 levels either between
resting and activated T cells or comparing exon 5 with the neigh-
boring exons. This indicates that these epigenetic marks are not
modulated in the CD6 gene by T cell activation, and they do not
have a function in CD6 alternative splicing.
It has been shown that active genes show altered H3K9 acety-
lation levels upon T cell activation (45). We thus characterized
histone H3K9 acetylation in CD6 in resting and activated T cells
(Fig. 3A). By contrast with the methylation marks analyzed, we
detected an overall increase in H3K9Ac in activated T cells. These
differences are statistically significant at the 59 end of the gene as
expected and also in exon 5. Treatment of HeLa cells with
inhibitors of histone deacetylases (HDACs) have been shown to
FIGURE 1. CD6Dd3 is upregulated upon T cell activation. (A) Sche-
matic representation of CD6 exon 5 alternative splicing pattern in resting
and activated T cells (left panel). CD6 full-length and CD6 alternative
isoform, CD6Dd3, protein representation (right panel). (B) Semiquantita-
tive RT-PCR analysis of CD6 exon 5 alternative splicing pattern in resting
and PHA-stimulated PBMCs. (C) Graphic representation showing the ratio
between exon 5 containing isoform (FL) and the isoform that lacks exon 5
(Δd3) in resting and activated state. Error bars represent SEM. n = 3. The
asterisk indicates statistical significance (*p , 0.05, Student t test).
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cause alterations in the splicing pattern of alternatively spliced
exons (46). We thus hypothesized that upon T cell activation, the
CD6 gene could undergo alterations in the chromatin structure to
facilitate the accessibility of the transcription machinery, resulting
in the increased CD6 mRNA levels and exon 5 skipping observed.
When we treated T cells with an inhibitor of HDACs (TSA), an
increase in the levels of transcripts lacking exon 5 was observed
(Fig. 3B), suggesting that the open chromatin state promotes
skipping of exon 5. Conversely, when T cells were incubated with
an inhibitor of topoisomerase I, camptothecin, which hampers
RNA pol II elongation, the opposite effect in the alternative
splicing pattern was observed: inclusion of exon 5 was promoted
(Fig. 3B). We quantified both CD6 mRNA isoforms and confirmed
that TSA as well as camptothecin have significant but opposite
effects in the splicing pattern of exon 5 (Fig. 3C), suggesting that
the RNA pol II transcription rate plays a determinant role in the
skipping or inclusion of exon 5 in CD6 pre-mRNA.
CD6 intron 4 contains a complex set of splicing regulatory
elements
Using the UCSC Genome Browser, we found several peaks of
conservation in intron 4, distant from the splice sites. These are
FIGURE 2. Characterization of RNA pol II occupancy levels and CD6 expression in resting and activated T cells. (A) Schematic representation of human
CD6 locus. Exons are represented by boxes, and introns are shown as a thin line. The region for specific qPCR primers pairs is underlined. (B) Graphic
representation of RNA pol II occupancy levels in CD6 gene in resting and activated T cells evaluated by ChIP assays showing an increase of RNA pol II
occupancy upon T cell activation (n = 5). (C) CD6 expression levels in resting and activated PBMCs were analyzed by qPCR, revealing an increase of
expression upon cell activation with PHA (n = 3). Error bars represent SEM. The asterisk indicates statistical significance (*p , 0.05 Student t test).
FIGURE 3. CD6 H3K9Ac levels in resting and activated T cells and CD6 chromatin structure modulation. (A) Graphic representation of H3K9Ac levels
in CD6 gene in resting and activated T cells evaluated by ChIP assay shows an increase of acetylation upon T cell activation. (B) Semiquantitative RT-PCR
showing the TSA and camptothecin effects in CD6 exon 5 alternative splicing pattern. (C) CD6 isoform expression levels were analyzed by qPCR. Primers
were designed to span the 4 to 5 and 4–6 exon junction regions. Error bars represent SEM. n = 3. The asterisk indicates statistical significance (*p , 0.05,
Student t test).
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conserved in 46 species of vertebrates, suggesting the presence of
important regulatory elements (Supplemental Fig. 3A).
We therefore generated a functional minigene containing the
genomic fragment spanning exons 4–6 to characterize the cis
elements involved in CD6 alternative splicing (Supplemental Fig.
3B). Importantly, when transfected into PBMCs, this minigene
recapitulates the alternative splicing pattern of the endogenous
CD6 gene, with the majority of transcripts containing exon 5
(Supplemental Fig. 3C, left panel). Moreover, upon PHA-induced
T cell activation, there is the same enrichment of CD6Dd3 over
CD6FL as observed in endogenous CD6 (Supplemental Fig. 3C,
right panel, compared with Fig. 1B, Supplemental Fig. 1). This
indicates that the minigene contains all of the necessary sequences
to promote CD6 exon 5 alternative splicing and can be used to
characterize the cis-regulatory elements involved.
To characterize the conserved region in intron 4, we engineered
the minigene to introduce specific deletions originating the con-
structs depicted in Fig. 4A. Minigene mutant i4D1, containing
a 436-nt deletion in the central region of intron 4 (nt 193–629)
(Fig. 4A), was transfected into resting T cells, and the splicing
pattern was analyzed by RT-PCR. A complete switch in exon 5
alternative splicing was observed, with a .3-fold reduction in the
mRNA isoforms ratio (relative increase of CD6Dd3 over CD6FL)
(Fig. 4B). A mutant having a smaller deletion (i4D6) induced
a statistically significant similar reduction, indicating that an ISE
for exon 5 inclusion is contained in the region between nt 297 and
629 of intron 4 (Fig. 4B). This is a sequence-specific effect, as
confirmed by replacement of the i4 297–629 sequence by an un-
related sequence (i4D6 crtl) (Fig. 4B).
To fine-map the ISE identified, three mutants containing dele-
tions of ∼100 nt were generated, each one lacking one-third of the
i4D6 deleted region (A, D297–383; B, D384–481; and C, D482–
629), and transfected into T cells (Fig. 4C). Intriguingly, deletion
of any of the three regions (A, B, and C) induced only a partial 2-
fold reduction in the CD6FL/CD6Dd3 ratio when compared with
unmodified i4 (Fig. 4C), suggesting that several regulatory ele-
ments may be present. To further dissect this region, mutant mini-
genes having combined or overlapping sequences excluded in
the nt 297–629 region were transfected and their splicing pattern
analyzed (Fig. 4D). Deletion of nt 297–481 (AB) induced a re-
duction of ∼3-fold in the CD6FL/CD6Dd3 isoforms ratio com-
pared with wild-type (WT) i4. By contrast, mutant BC (D384–
629) did not induce any alterations in the ratio (Fig. 4D). In ad-
dition, deleting regions A and C together again introduced a sig-
nificant reduction in the CD6FL/CD6Dd3 ratio (Fig. 4D). Taken
together, these results suggest that both silencer and enhancer
elements coexist in region BC, as contrasted with the effect (in-
creased exon 5 skipping) of deleting regions B or C indepen-
dently; deletion of B together with C (BC) does not result in
significant differences in comparison with the WT. We therefore
constructed an additional mutant (D, D451–544) for which the
deleted sequences comprise part of region B and part of region C.
Interestingly, this deletion causes a significant increase in exon 5
inclusion (2-fold increase in the CD6FL/CD6Dd3 ratio), sug-
gesting that it contained an inhibitory sequence for exon 5 in-
clusion (Fig. 4E).
CD6 exon 5 alternative splicing is regulated by SRSF1, SRSF3,
and hnRNPA1
As alternative splicing of exon 5 of the CD6 gene is regulated by
T cell activation, we investigated variations in the expression of
relevant splicing factors in resting and activated T cells by RT-
FIGURE 4. Mapping of regulatory regions in intron 4. (A) Different mutants, each one having different deletions in intron 4, were created by PCR-
directed mutagenesis and used for transient transfection in human T cells. (B–D) Graphic representation of the CD6FL/CD6Dd3 ratios in intron 4 mutants
and CD6 WT minigene determined by semiquantitative RT-PCR. (E) Schematic representation of intron 4 regulatory elements. Error bars represent SEM.
n = 3; (E) n = 2. The asterisks indicate statistical significance (*p , 0.05, **p , 0.01, Student t test). E, enhancer; S, silencer.
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qPCR and immunoblotting. Within the nt 297–629 regulatory
sequence of intron 4, there are several putative binding sites for
splicing factors such as SRSF1, SRSF2, SRSF3, SRSF5, SRSF6,
hnRNPA1, hnRNPAB, hnRNPH/F, and PTB as determined by
bioinformatics analyses (SFmap Web site: http://sfmap.technion.
ac.il/index.html). We focused on those presenting the highest
SFmap algorithm scores (i.e., SRSF1, SRSF3, and hnRNPA1).
Upon PHA-induced T cell activation, there were no significant
alterations in mRNA or protein expression of either hnRNP A1 or
SRSF3 (Fig. 5A, 5B); however, SRSF1 mRNA and protein levels
were decreased by ∼50% in activated T cells. To investigate the
role of differential SRSF1 levels in CD6 alternative splicing, we
used siRNA depletion and overexpression assays. Remarkably,
overexpression of SRSF1 resulted in 75% reduction in the ex-
pression of the CD6Dd3 isoform (Fig. 5C). Overexpression
of SRSF3 and hnRNPA1 also induced significant changes in
CD6Dd3 expression (2-fold decrease and 1.5-fold increase, re-
spectively), suggesting that changes in their protein expression, if
produced, may also affect CD6 alternative splicing (Fig. 5C). The
converse effect on CD6Dd3 isoform expression was observed
when all of these splicing factors were siRNA knocked down
individually (Fig. 5D).
Given the observed decrease in SRSF1 expression upon T cell
activation and the effect of this factor on CD6 alternative splic-
ing, we hypothesized that the lower recruitment of SRSF1 to the
regulatory element of intron 4 was the limiting factor for exon 5
inclusion. To investigate this, we performed RIP with a specific
Ab for SRSF1 and CD6 primers. Indeed, upon cell stimulation
with PHA, a marked decrease of the recruitment of SRSF1 to
the intron 4 was evident when compared with untreated cells
(Fig. 5E). Importantly, recruitment of SRSF1 to CD6 was also
prevented by TSA. As SRSF1 protein levels are not altered by
TSA treatment (Fig. 5F), these results suggest that recruitment of
SRSF1 to CD6 pre-mRNA is acetylation dependent.
To demonstrate that SRSF1 binds to i4D6, we performed UV
crosslinking and immunoprecipitation assays using the sequence
deleted from i4D6 as a pre-mRNA template. As can be seen,
SRSF1 binds to this element in intron 4 (Fig. 5G). Overall, our
results suggest that not only is SRSF1 less expressed upon T cell
activation, but it is also strikingly less recruited to an ISE present
in intron 4 of the CD6 primary transcript, all resulting in signifi-
cant increase of exon 5 skipping (Fig. 6).
Discussion
Upon Ag recognition, T cell activation is determined by the balance
between activatory and modulatory signals. The first type of signals
include the affinity of a given TCR to a specific antigenic peptide
presented in the context of MHC complexes displayed at the
surface of APCs and also all of the signaling machinery that relays
the information received at the cell surface down to the nucleus.
This consists of a well-structured pathway that sequentially acti-
vates effector enzymes and adapters, such as the Src family kinases
Lck and Fyn that phosphorylate the ITAMs of the CD3 complex
and the kinase ZAP70 that, upon binding to phosphorylated ITAMs,
becomes activated and phosphorylates the membrane adapter LAT,
which in turn serves as a docking platform for many downstream
effectors such as PLC-g, PI3K, GADS, Grb2/Sos1 connecting to
the Ras–MAPK pathway, Itk, and SLP-76, among others (47).
FIGURE 5. SRSF1 regulates CD6 exon 5 alternative splicing and is less recruited to CD6 pre-mRNA upon T cell activation. (A) qPCR analysis of
SRSF1, hnRNPA1, and SRSF3 expression levels in resting and activated T cells. (B) SRSF1, hnRNPA1, and SRSF3 protein levels in resting and activated
T cells. (C) Graphic representation of the quantification of CD6Dd3 isoform expression levels upon SRSF1, hnRNPA1, or SRSF3 overexpression (OE). (D)
Graphic representation of the quantification of CD6Dd3 isoform expression levels upon SRSF1, hnRNPA1, or SRSF3 knockdown (KD). (E) RIP showing
SRSF1 recruitment levels to CD6 primary transcript intron 4 in resting untreated T cells or PHA- or TSA-treated PBMCs. (F) SRSF1 proteins levels in
untreated and TSA-treated T cells. (G) UV-crosslinking and immunoprecipitation showing SRSF1 binding to i4D6 sequence. Error bars represent SEM.
n = 3. The asterisks indicate statistical significance (*p , 0.05, **p , 0.01, Student t test).
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In contrast, there are a few receptors such as CD5 and CD6 that
limit TCR-mediated responses at the onset of activation. In the case
of CD5, this is achieved through the phosphorylation-dependent
recruitment of signaling inhibitory enzymes such as the phos-
phatase Src homology region 2 domain-containing phosphatase-1,
the ubiquitin ligase Cbl, and the Ras GTPase-activating protein (48,
49). The kinases that promote these associations by phosphory-
lating tyrosine residues of the cytoplasmic tail of CD5 are the
same Lck and Fyn that induce positive signaling via the TCR/CD3
complex, although subsequently, CD5 activation can nonetheless
modulate the kinase’s activity (50, 51). Regarding CD6, it is still
not clear how signaling attenuation is achieved, as none of the
CD5-associated inhibitors have been reported to associate with
CD6. On the contrary, upon activation and phosphorylation, CD6
becomes packed with effector enzymes and adapters such as Lck,
Fyn, ZAP70, Itk, and SLP-76, all connoted with productive sig-
naling and full T cell activation (3, 6).
One hypothesis to explain the inhibitory properties of CD6 is
that the receptor may function as a decoy adapter, having high
affinity for the signaling mediators and thus removing much of the
activation potential away from the sites of TCR-mediated signaling
initiation. On this line, it is attractive to ponder that upon T cell
activation, to promote the skipping of the exon that encodes the
ligand-binding domain is a very enticing way of removing this
inhibitory receptor away from the IS and thus favors a stronger
stimulus. In the current study, we focused on the identification of
CD6 exon 5 alternative splicing regulatory elements and factors
that are induced following T cell activation and have a striking
impact on the subcellular localization of CD6 or, more appropri-
ately, the alternative isoform CD6Δd3.
Although this strategy to remove inhibition from the sites of
activation may appear complex and intricate, the molecular
mechanisms used to induce exon 5 skipping revealed to be sur-
prisingly and paradoxically simple. An increase in CD6 expression
due to T cell activation was corroborated by augmented RNA pol
II occupancy (Fig. 2) and by a boost in histone acetylation levels
(Fig. 3C) in the CD6 gene, leading to a more accessible chromatin
state and thus facilitating CD6 transcription and exon 5 skipping.
Splicing and polyadenylation are predominantly cotranscrip-
tional events, allowing for crosstalk between these processes. In
particular, the RNA pol II transcription elongation rate was
demonstrated to affect alternative splicing (52), and we have
previously shown the same effect in alternative polyadenylation
(53). According to the RNA pol II kinetic coupling model that
integrates alternative splicing with transcription kinetics, an in-
crease of the RNA pol II elongation rate affects exon inclusion,
depending on the strength of the splice sites (54).
Kadener et al. (38) showed that a compact chromatin structure
of a replicated reporter plasmid acted as a barrier to RNA pol II
elongation, leading to a higher exon inclusion. This effect was
reverted by inhibition of HDAC, using TSA, promoting histone
acetylation and a subsequent chromatin opening. Schor and col-
laborators (39) characterized a change in chromatin structure upon
neuronal cell depolarization that induces the skipping of the al-
ternative exon 18 of NCAM mRNA. These results led us to
hypothesize that the chromatin structure could affect exon 5 al-
ternative splicing and prompted us to investigate the H3K9 acet-
ylation profile of the CD6 gene. Our results showed that T cell
treatment with the HDAC inhibitor TSA promotes skipping of
exon 5, mimicking the effect of T cell activation on CD6 alter-
native splicing. Conversely, when we decreased the RNA pol II
elongation rate, we promoted inclusion of exon 5 (Fig. 3B).
Taken together, our results indicate that the chromatin structure
alterations that occur upon T cell activation and an increase in the
transcription rate of CD6 may favor exon 5 skipping from the
mature mRNA. The fact that the most mature rat single-positive
thymocytes, which have higher CD6 expression than double-
positive thymocytes, present increased levels of exon 5 skipping
seems to corroborate our interpretation that the levels and rate of
transcription of the CD6 gene are coresponsible for the generation
of an alternative transcript.
The selection of 59 and 39 splice sites in pre-mRNA is governed
in part by RNA sequences, the “splicing code,” and RNA binding
proteins (55–57). To investigate the importance of RNA motifs
and the trans-acting factors in the regulation of CD6 alternative
splicing, we used a minigene that mimics the endogenous CD6
FIGURE 6. Proposed model of
CD6 exon 5 alternative splicing
regulation upon T cell activation.
Resting T cells present basal CD6
H3K9 acetylation levels, and SRSF1
is efficiently recruited to an intron 4
enhancer (green rectangle), leading
to preferential inclusion of exon 5 in
the CD6 pre-mRNA. In activated
T cells, there is an increase in CD6
H3K9 acetylation levels and a de-
crease in the recruitment of SRSF1
to the ISE, causing an increase
in exon 5 skipping and CD6Dd3
mRNA production.
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exon 5 splicing event. We identified a highly conserved regulatory
element localized in intron 4 containing a complex set of splicing
enhancers and silencers that strongly regulates exon 5 inclusion.
As this element contains putative binding sites for several splicing
factors, we quantified the expression of these splicing factors in
resting and activated T cells. Surprisingly, we observed that the
expression of SRSF1 was decreased upon T cell activation,
whereas that of hnRNP A1 and SRSF3 remained approximately
constant. We also showed that all three factors can affect CD6
alternative splicing (SRSF1 and SRSF3 promote exon 5 inclusion,
and hnRNPA1 increases exon 5 skipping), but only SRSF1 had its
expression effectively decreased in activated T cells. SRSF1 is
a prototype member of the serine/arginine-rich protein family of
splicing factors with a role in alternative splicing (58–61). SRSF1
has been extensively studied; however, only a few endogenous
target genes have been identified (62–65). Our results indicate
that, upon T cell activation, the deficit of SRSF1 may be crucial
for exon 5 exclusion, with SRSF1 most likely becoming a limiting
factor for the increased levels of CD6 transcription and CD6Dd3
mRNA increase detected upon T cell activation.
Using RIP, we detected a decrease of SRSF1 recruitment to the
CD6 primary transcript in activated T cells that could be explained
not only by a decrease of SRSF1 expression, but also by the effect
that an increased chromatin acetylation level has in the recruitment
of this splicing factor, as shown by others (39). Our ChIP experi-
ments for H3K9ac revealed an increase of CD6 acetylation level
upon T cell activation. Accordingly, when we treated cells with
TSA, we observed less SRSF1 recruitment to the CD6 primary
transcript. A similar effect was observed in neuroblastoma cells by
Schor and collaborators (66), showing that chromatin acetylation
upon cell membrane potential depolarization led to an accumu-
lation of SRSF1 in the nuclear speckles, being less recruited to the
primary transcripts compromising the splicing of nascent RNA.
Although it was previously shown that TSA treatment did not affect
the acetylation levels of T7-tagged SRSF1 transfected into HEK-
293T cells (66), it is still possible that TSA causes SRSF1 acety-
lation, leading to a differential recruitment to CD6 pre-mRNA. In
fact, acetylation of nonhistone proteins such as SRSF2 was already
described and promotes its proteosomal degradation (67).
The working model we propose for the regulation of CD6 exon
5 alternative splicing upon T cell activation is depicted in Fig. 6. In
resting conditions, T cells have a basal CD6 transcription level,
with sufficient SRSF1 levels to bind to the intron 4 regulatory
element. In these conditions, SRSF1 promotes the inclusion of
exon 5 in the majority of mature mRNAs. Upon T cell activation,
an increase of CD6 acetylation levels and a consequent chromatin
structure modification facilitates CD6 transcription. Under these
activation conditions, there is a deficient recruitment of SRSF1 to
intron 4, which is necessary for exon 5 inclusion, leading to exon
skipping and the production of CD6Dd3. Taken together, we
showed that the human T cell activation–induced alternative
splicing of the CD6 gene is regulated at multifactorial levels, with
chromatin structure, transcription rate, and splicing factor SRSF1
having fundamental roles. As CD6 has been associated with
several autoimmune diseases, the molecular mechanisms reg-
ulating CD6 alternative splicing upon activation of human T cells
provide new insight into a physiologically relevant molecule.
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